Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development. By combining molecular targeting with controlled radiation delivery, these therapies introduce a ...
Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an ...
Polyrizon Ltd., a biotechnology company focused on intranasal drug delivery systems, has reported promising preclinical results for its hydrogel-based Trap & Target (T&T) platform, developed in ...
Preclinical toxicology studies face a significant challenge: animal models cannot self-report side effects. This limitation proves particularly problematic when evaluating treatments for which subtle ...
LILLE, France & PARIS--(BUSINESS WIRE)--Regulatory News: Dev4All, 4P-Pharma's cutting-edge R&D booster, announces a strategic collaboration with Pharmaseed, an established Contract Research ...
Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sail Biomedicines, a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that it will present new preclinical data from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results